Citi Pharma Limited reported a net profit of Rs 233.23 million for the period ended September 30, 2026
Filed as: Financial Results for the Quarter Ended 30 September 2026
Summary
Citi Pharma Limited reported a net profit of Rs 233.23 million for the period ended September 30, 2026, with a slight increase in revenue to Rs 3.36 billion. The company showed improved profitability despite a decrease in cash and cash equivalents.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Net Profit | PKR 233.23 M | PKR 203.69 M | +14.5% |
| Revenue | PKR 3,363.46 M | PKR 3,370.25 M | -0.2% |
| Earnings per Share | PKR 1.02 | PKR 0.89 | +14.6% |
| Cash and Cash Equivalents | PKR 268.19 M | PKR 910.95 M | -70.5% |
| Gross Profit | PKR 626.04 M | PKR 518.97 M | +20.6% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Net profit increased to Rs 233.23 million, up from Rs 203.69 million in the prior period, reflecting a growth of 14.51%.
- Revenue remained stable at Rs 3.36 billion compared to Rs 3.37 billion in the prior period, showing a slight decline of 0.20%.
- Earnings per share improved to Rs 1.02 from Rs 0.89, indicating enhanced shareholder value.
Citi Pharma Ltd. (CPHL) on Nafa
Last price Rs 64.00 · Pharmaceuticals · You can own CPHL shares from your phone.
More CPHL announcements
- NoticeTransmission of Quarterly Report for the Period Ended 30 September 2026
- NoticeBoard Meeting In Progress
- Material informationCiti Pharma Acquires 20% of Pakheim InternationalCiti Pharma Limited acquires 20% shareholding in Pakheim International Pharma, marking the first step towards full acquisition.
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeChange of Chief Financial Officer
- NoticeBoard Meeting
Source: Citi Pharma Ltd.'s filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.